Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-25-013251
Filing Date
2025-04-10
Accepted
2025-04-10 16:07:18
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20043533x2_defa14a.htm DEFA14A 9215
2 ny20043533x2_nc01.jpg GRAPHIC 1254554
3 ny20043533x2_nc02.jpg GRAPHIC 1511468
  Complete submission text file 0001140361-25-013251.txt   3815803
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-29889 | Film No.: 25828402
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)